Arca
Skip to content
Tools
Tools

FOLR1: Folate receptor alpha

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on FOLR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Antibody-drug conjugate
  • Other

Approved1

  • Mirvetuximab soravtansine

Phase 32

  • Farletuzumab
  • Vintafolide

Phase 21

  • Mirvetuximab

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • CSPC Megalith Biopharmaceutical Co.,Ltd.125%
    • Endocyte125%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Antibody250%
    • Antibody-drug conjugate125%
    • Other125%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Folate receptor alpha binding agent; the rest name their own mechanism.
    Mirvetuximab soravtansineApprovedAbbVieAntibody-drug conjugateBinding agent—21Boxed warning
    FarletuzumabPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.AntibodyInhibitorFolate receptor alpha inhibitor2—
    VintafolidePhase 3EndocyteOtherBinding agent—0—
    MirvetuximabPhase 2AbbVieAntibodyBinding agent—22—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
    MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerMirvetuximab soravtansine, MirvetuximabPhase 2Not yet recruitingTongji Hospital2026-11-12
    Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal CancerMirvetuximab soravtansine, Mirvetuximab—RecruitingAbbVie2026-10-27
    Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerMirvetuximab soravtansine, MirvetuximabPhase 2Not yet recruitingFudan University2026-09-17
    89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian CancerMirvetuximabEarly phase 1Not yet recruitingPeking University Cancer Hospital & Institute2026-08-27
    A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid TumorsFarletuzumabPhase 1 / Phase 2RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2026-08-04
    Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerMirvetuximab soravtansine, MirvetuximabPhase 2Not yet recruitingPeking University Third Hospital2026-08-03
    A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α(FRα)Mirvetuximab soravtansine, Mirvetuximab—Not yet recruitingNING LI-GYN2026-07-08
    A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World SettingMirvetuximab soravtansine, Mirvetuximab—Not yet recruitingAbbVie2026-07-07
    AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerMirvetuximab soravtansine, MirvetuximabPhase 3RecruitingAstraZeneca2025-10-20
    A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerMirvetuximab soravtansinePhase 3RecruitingEli Lilly and Company2025-10-09
    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesFarletuzumabPhase 1 / Phase 2RecruitingEisai Inc.2020-03-09

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Neurodegenerative syndrome due to cerebral folate transport deficiency
    0.81
    Neoplasm
    0.50
    Fallopian tube neoplasm
    0.46
    Peritoneal neoplasm
    0.46
    Malignant epithelial tumor of ovary
    0.45
    Seizure
    0.41
    Primary peritoneal carcinoma
    0.39
    Ovarian neoplasm
    0.38
    Ovarian carcinoma
    0.37
    Hereditary disease
    0.34

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2121, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P15328, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.